论文部分内容阅读
目的 比较达利珠单抗和OKT3预防肾移植术后早期急性排斥反应的效果。方法 肾移植受者在使用环孢素A(或他克莫司 )、霉酚酸酯及激素预防急性排斥反应的基础上加用达利珠单抗 (42例 )或OKT3(12 8例 ) ,观察 2个组肾移植术后 3个月内急性排斥反应发生率。结果 肾移植术后 3个月内 ,使用达利珠单抗者急性排斥反应发生率为 2 .4 % ,明显低于使用OKT3者的13.3% (P <0 .0 5 ) ,且前者无耐激素者 ,急性排斥反应的发生时间推迟 ,血肌酐恢复正常的时间也早于使用OKT3者。结论 达利珠单抗预防肾移植术后急性排斥反应的效果优于OKT3。
Objective To compare the effects of daclizumab and OKT3 in preventing early acute rejection after renal transplantation. Methods Renal transplant recipients received daclizumab (42 cases) or OKT3 (128 cases) on the basis of cyclosporine A (or tacrolimus), mycophenolate mofetil and hormones to prevent acute rejection. The incidence of acute rejection within 3 months after renal transplantation in 2 groups was observed. Results Within 3 months after renal transplantation, the incidence of acute rejection with daclizumab was 2.3%, significantly lower than that with OKT3 (13.0%, P <0.05), and the former had no resistance Hormone, delayed onset of acute rejection, serum creatinine returned to normal earlier than OKT3. Conclusion Dalyuzumab is superior to OKT3 in preventing acute rejection after renal transplantation.